Affibody is a biotechnology company developing next generation radiopharmaceuticals based on our proprietary Affibody® platform
Affibody is strategically focused on advancing our pipeline of radioligand therapeutics that offer a competitive advantage and significant opportunities to benefit cancer patients. Our pipeline also includes partnership programs in immunology.
event
15 Sep
Morgan Stanley 24th Annual Global Healthcare Conference September 15, 2026, New York
event
17 Sep
4th Annual Oppenheimer Targeted Radiopharmaceutical Therapies Summit September 17, 2026, New York
event
29 Sep
CHI: Discovery on Target – Radioligand Therapies September 29 – October 1, 2026, Boston, YSA
There are currently no posts in the reports and events archive.
Regulatory
2026-08-27
Affibody to Participate in Upcoming Healthcare Investor Conferences
Regulatory
2026-05-28
It is the competence and the engagement of all coworkers that make Affibody an inspiring and exciting place to work at. We know we reach much further in innovation, efficiency, and quality by having a work place where we as coworkers care for each other, are ambitious and know and value our own contribution to the end result.